论文部分内容阅读
目的 探讨奎硫平对儿童青少年精神分裂症治疗的临床疗效和安全性。方法 对 2 7例首次住院的儿童青少年精神分裂症病人使用奎硫平 15 0～ 60 0mg/d治疗 8周 ,以阳性与阴性症状量表 (PANSS)评定疗效 ,用不良反应症状量表 (TESS)评估安全性。结果 PANSS总分治疗后与治疗前有显著性差异 (P <0 0 0 1)。不同疗效组间奎硫平的治疗量及血药浓度无显著性差异 (P >0 0 5 )。奎硫平治疗 8周内 ,无严重不良反应影响继续治疗。结论 奎硫平能缓解儿童青少年精神分裂症的精神病性症状 ,且耐受性较好
Objective To investigate the clinical efficacy and safety of quetiapine in the treatment of schizophrenia in children and adolescents. Methods Twenty-seven first-born children and adolescents with schizophrenia were treated with quetiapine 15 0 ~ 60 0 mg / d for 8 weeks. The positive and negative symptom scales (PANSS) were used to evaluate the curative effect. The adverse reaction symptom scale (TESS ) Evaluate safety. Results The total score of PANSS after treatment was significantly different from that before treatment (P <0.01). There was no significant difference in the therapeutic amount and plasma concentration of quetiapine among different treatment groups (P> 0.05). Quetiapine treatment within 8 weeks, no serious adverse reactions continue treatment. Conclusions Quetiapine can alleviate the psychotic symptoms of schizophrenia in children and adolescents and is well tolerated